Lithium-Induced Hyperparathyroidism: An Ill-defined Territory

Vishwanath Pattan; Balwinder Singh; Sahar S Abdelmoneim; Chaitra Gopinath; Vishnu Sundaresh

Lithium-Induced Hyperparathyroidism: An Ill-defined Territory

Psychopharmacol Bull. 2021 Jun 1;51(3):65-71.

Authors

Vishwanath Pattan¹, Balwinder Singh¹, Sahar S Abdelmoneim¹, Chaitra Gopinath¹, Vishnu Sundaresh¹

Affiliation

¹ Pattan, MD, Division of Endocrinology, Wyoming Medical Center, Casper, Wyoming, USA. Singh, MD, MS, Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA. Abdelmoneim, MD, MSc, MS, Research Collaborator, Cardiovascular Ultrasound Imaging and Hemodynamic Laboratory, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA. Gopinath, MD, Department of Internal Medicine, University of Kansas, Wichita, Kansas, USA. Sundaresh, MD, MS, Division of Endocrinology, University of Utah School of Medicine, Salt Lake City, Utah, USA.

PMID: 34421145
PMCID: PMC8374931

Abstract

Lithium is the gold standard treatment for bipolar disorder. Studies have shown an association between lithium and hyperparathyroidism. However, there is limited data regarding the management of lithium-induced hyperparathyroidism. We present a clinical conundrum which physicians frequently encounter-an excellent lithium responder refractory to other treatments who developed lithium-induced hyperparathyroidism. Medical treatment with cinacalcet was successful in management of hyperparathyroidism without discontinuing lithium maintenance therapy.

Keywords: bipolar disorder; cinacalcet; hypercalcemia; hyperparathyroidism; lithium.

Publication types

Case Reports

MeSH terms

Bipolar Disorder* / drug therapy
Cinacalcet
Humans
Hypercalcemia*
Hyperparathyroidism* / chemically induced
Lithium

Substances

Lithium
Cinacalcet